Jiang Xu
About Jiang Xu
Jiang Xu is a Senior Scientist at Virogin Biotech in Vancouver, Canada, where he leads a research group focused on mRNA-based immunotherapeutics. He has an extensive academic background with degrees in Biomedical Engineering, Nanotechnology, and Polymer Science, and has contributed to significant research in vaccine development.
Work at Virogin Biotech
Jiang Xu has served as a Senior Scientist at Virogin Biotech since 2021, contributing to the company's research efforts in Vancouver, British Columbia, Canada. In this role, he leads a research group focused on developing novel mRNA-based immunotherapeutics. His work integrates principles of fluidic mechanics and soft matter to advance the field of immunotherapy.
Education and Expertise
Jiang Xu holds a Doctor of Philosophy (PhD) in Nanotechnology from the University of Waterloo, obtained between 2013 and 2016. He also completed a PhD in Physical Chemistry at Université de Bordeaux during the same period. His academic background includes a Master of Science (M.Sc.) in Biomedical Engineering from The Chinese University of Hong Kong and a Bachelor of Engineering (B.E.) in Polymer Science and Engineering from Beijing University of Chemical Technology. His expertise lies in drug encapsulation and formulation, particularly related to mRNA vaccines and controlled release systems.
Research Experience
Prior to his current position, Jiang Xu gained extensive research experience through various roles. He worked as a Postdoctoral Research Fellow at Harvard University from 2019 to 2021 and at Ryerson University from 2018 to 2019. He also completed a postdoctoral position at ESPCI ParisTech, where he contributed to advancements in microfluidics and soft matter. His research has led to significant publications, including studies on mRNA vaccines for HPV-related cancer and Monkeypox.
Publications and Contributions
Jiang Xu has contributed to several notable publications in the field of immunotherapy and vaccine development. His work includes a publication on an mRNA vaccine targeting HPV-related cancer and involvement in research published in Nature Communications regarding a Monkeypox mRNA vaccine. He also participated in a study on a homologous prime boost strategy using HER-2 expressing oncolytic HSV-1, which was published in the journal Vaccines.
Previous Positions
Jiang Xu has held various positions throughout his career, including Principal Scientist at Boston Molecules from 2020 to 2021 and Research Associate at St. Michael from 2018 to 2019. He has also worked as a Research Intern at the Chinese Academy of Sciences and as a Research Assistant at The Chinese University of Hong Kong. His diverse experiences across different institutions have enriched his research capabilities and expertise.